AzurRx (AZRX) Corporate Media Kit

32 Open-label PERT + MS1819 15 days each dose Follow-up 12-15 days V4 Visit Inpatient CFA measurement V7 Eligibility criteria CFA < 80% Screening 0-15 days Inclusion 15 days Inclusion + MS1819 700mg/d + MS1819 1120mg/d + MS1819 2240mg/d V1 V3 V5 V6 V2 Screening Stable PERT dose M/F ≥ 12 years N = 24 patients Duration: 100 Days European Trial Sites (Hungary, Spain, Turkey ) Phase 2 Combination Therapy (PERT + MS1819) Trial Design Study Initiated Q4 2019, Anticipated Completion Q2 2021